Becton, Dickinson and Company (BDX)

In the past six months, BDX stock has been impacted by several key events. BD reported stronger-than-expected Q2 fiscal 2026 results and raised its full-year adjusted EPS guidance, leading to a stock price increase. BD executed a $2.0 billion accelerated share repurchase program and retired $2.1 billion of debt, which was viewed positively by investors. Vitor Roque was named Executive Vice President and Chief Financial Officer. BD completed the spin-off of its Biosciences and Diagnostic Solutions business, leading to a downward revision of full-year earnings guidance and causing some intraday volatility. Analysts have adjusted their price targets for BDX, with some raising targets following the positive Q2 results.

Specific detailed seasonal patterns for Becton, Dickinson & Co.'s products and services are not explicitly provided in the available information. The company's revenue figures show quarterly fluctuations, but these are not definitively attributed to seasonal demand for specific products.

Becton, Dickinson & Co. (BDX) is a global medical technology company focused on integrating innovative products and services to address critical healthcare needs. The company generates revenue through the sale of medical devices, diagnostic instruments, and consumables. BD operates through several key segments including BD Medical, which focuses on medication delivery and management; BD Life Sciences, dedicated to diagnostics and research; BD Interventional, concentrating on minimally invasive surgical procedures; Medical Essentials, encompassing legacy medical surgical units; Connected Care, featuring products like the Alaris infusion pump; and Biopharma Systems, producing prefillable syringes and autoinjectors.

Becton, Dickinson & Co. has a significant global presence, operating in more than 190 countries and employing over 75,000 people worldwide. International revenue accounts for a substantial portion of its business, with sales distributed across the United States, Europe/Middle East/Africa, Asia, and other regions. The company has manufacturing operations in numerous countries and regional offices and headquarters are located in places such as Franklin Lakes, New Jersey, Singapore, San Diego, Mississauga, Sydney, Heidelberg, and Shanghai.

In December 2024, Becton, Dickinson and Company agreed to an $85 million settlement with investors regarding claims about the Alaris infusion pumps. The U.S. Securities and Exchange Commission (SEC) announced settled charges against BD, requiring the company to pay a $175 million civil penalty for misleading investors about risks associated with the Alaris infusion pump and for overstating its income. These events negatively impacted the company's reputation.

Becton, Dickinson & Co.'s shareholder base is predominantly composed of institutional investors including Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Institutional holders collectively hold a significant portion of outstanding shares, estimated to be around 89% by mid-2025. Insider trading activity in the past six months has primarily involved sales by officers.